Key Takeaways
- Supply chains held, but costs bit: Geopolitical disruption in West Asia triggered force majeure, freight spikes and container shortages, yet Divis avoided any revenue loss and kept material availability manageable through proactive procurement.
- Generic volumes steady, pricing still competitive: The base business delivered stable volumes across key products, with recent API revenue pickup driven by existing portfolio volume rather than new launches.
- Custom Synthesis pipeline is active but timelines are not the company's to call: Three dedicated CS projects have cleared validation and await customer regulatory approvals; management is hopeful for 2027 commercialization but stresses the timeline depends entirely on the customer.
- Peptide ambition is real and scaled: The company has validated several fragments, operates 3,000-liter SPPS capacity unmatched in India, and is targeting a position among the largest global players, though commercialization remains gated by customer qualification cycles.
- What to watch next quarter: Whether raw material cost inflation fully surfaces in Q1 margins, any progress on customer approvals for dedicated CS projects, and how much inventory builds as the company secures material ahead of logistics uncertainty.
Supply Chain & Cost Environment
- Geopolitics hit logistics hard: Escalation in West Asia disrupted trade routes, congested ports and extended transit times. Suppliers invoked force majeure, ocean and air freight rates rose considerably, and container and tank availability tightened. Despite this, critical raw material and solvent availability stayed broadly manageable.
- Procurement model absorbed the shock: A multi-year effort to broaden the supplier base and deepen domestic procurement paid off. Teams adopted proactive quarterly planning, securing supplies and managing inventory efficiently even with uncertain lead times. For time-sensitive solvents, tighter coordination between procurement, production and planning ensured continuity.
- Logistics execution protected revenue: Shipments were planned proactively with reliable long-standing partners, maintaining delivery consistency and honoring customer commitments. Management confirmed no revenue was lost to logistics issues in Q4.
- Cost pressures are real and rising: Raw material prices have increased, linked partly to crude oil moves. The company is factoring these in and trying to pass them on where feasible. Freight cost pressures are expected to continue in the near term and are incorporated into coming-quarter planning.
- Inventory is being deliberately built: The company is securing and storing material to ensure efficient manufacturing and outward logistics shipments. The inventory increase is expected to become visible from Q1 of next year, though management declined to quantify the build.
Nilima Prasad Divi: "Right now, we can say it is difficult, but it is not something that we are completely worried about."
Generic Business & Pricing
- Volume stability, not volume growth: Volumes across key products remained stable through the quarter and full year. The healthy API revenue pickup over the past two quarters came from volume traction in the existing portfolio, not from new molecules; the customer base has been quite steady.
- Pricing remains competitive: The pricing environment stays challenging, but steady demand across markets and healthy volume traction in products provided offset.
- Contract structures provide some protection: Most APIs in the generic segment are backed by long-term contracts with variability clauses, reviewed every three months or structured as direct raw-material-plus. These clauses protect against raw material price rises. Spot and quarterly negotiated buys exist in regions like South America, parts of Europe, Eastern Europe and Asia.
- New product opportunity is gated by customer launches: The company is waiting for customers to launch new portfolios in 2026-27 as products come off patent, which would provide the next leg of volume growth.
- Margin pressure has two roots: Generic pricing pressure and increased material costs. The cost increase began during COVID, had started settling down, but rose again with the war.
Custom Synthesis & Dedicated Capacity
- Pipeline is active, rotation is normal: Customer engagement remained strong and progressive through the year. The project pipeline stays active with molecules progressing through development toward near commercialization. The company does significant late-life-cycle management for customers: as a project nears patent expiry, volumes may decline, but several new projects enter the pipeline in a continuous rotation.
- Three dedicated CS projects are at the customer's door: All three have gone through various stages of validation and are in the process of being supplied to the customer. Commercialization now depends entirely on customer regulatory approvals. Management is hopeful for 2027 commercialization but stresses it could be earlier or later.
- The first dedicated contract (announced April 2024) is on a similar clock: Validation phases are completed and product has been supplied to customers. The original operational timeline pointed to January 2027; management now says commercialization is hopeful by 2027, earlier, or maybe later.
- Revenue recognition has no fixed date: For innovative products, the cycle depends completely on the customer's timeline because Divis files in the customer's CMC and has no control over launch. Management is optimistic about a two-year range but notes it could be as fast as six months or as long as three years.
- Unit 3 is steadily absorbing production: Operations at Unit 3 have progressed, playing an increasingly important role in backward integration. Through the year, select activities were gradually transferred from Units 1 and 2, freeing up GMP space and strengthening the supply chain. Transfers happen on a qualification-to-qualification basis with about two to four months of lead time.
Dr. Kiran S. Divi: "The cycle is typically when we do an innovative product, we completely depend on the customer's timeline because we file in their CMC. We do not have control on when the product will be launched. It can be wishful thinking if you want it in 6 months or 1 year, it can take 2 years."
Peptide Business
- Capability build is real and scaled: The company has several 3,000-liter SPPS systems, which management states no one else in India has. The stated ambition is to be one of the largest global players in the world.
- Validation milestones are accumulating: During the quarter, the company successfully validated several fragments with a few more in the pipeline. Divis remains closely engaged with multiple customers across different therapeutic categories.
- Customers are at various stages: Some are in validation, some in qualification, and some in R&D doing small quantities for fragments. The pipeline is described as healthy across different therapeutic segments.
- Commercialization timeline is unknowable: Validated fragments must go to customers and go through their qualification cycle. Management says it is difficult to put a timeline on any project, and declined to disclose details on chain length or whether fragments serve single or multiple products, citing confidentiality agreements.
Dr. Kiran S. Divi: "We have several 3,000-liter SPPS, which by far in India nobody has. We are quite strong and committed towards this segment, and we are targeting to be one of the largest global players in the world."
Contrast Media
- Iodine-based contrast media is commercial and growing: The company is already in commercial sales, tied up substantially with the innovator side, and supplying in several multiples of tons. These are backed by long-term contracts; some customers are increasing volume while others are keeping it steady.
- Gadolinium-based products are still pre-revenue: Molecules remain at the qualification stage, in Phase II and Phase III. Customers are buying quantities only for studies to qualify their product. Revenue will start as and when customers get approvals.
Margins & Profitability
- Management declined to give a margin figure: When asked about the FY27 margin outlook given cost pressures and new project commencements, management said it is difficult to project but expects margins to remain stable, adding that given the current situation they would not want to throw a figure on that.
- The 37-38% margin question went unanswered: When pressed on whether increasing CS mix could drive margins back toward historical peaks, Dr. Kiran Divi declined to answer, citing several unforeseen challenges that make commenting on margin difficult at this point.
- Cost pass-through is partial and negotiated: The company is trying to minimize the impact of ongoing cost increases by discussing with customers to keep numbers almost close to what is being achieved right now. On the generic side, long-term contract variability clauses provide some protection; on the CS side, the ability to pass through is less formulaic.
- Currency is a tailwind with a caveat: As an export-oriented company, currency depreciation would definitely benefit, but management noted that when the rupee drops it would also have an impact, without elaborating.
- One-time labour code charge booked: The notification of four Labour Codes effective November 21, 2025 triggered a one-time incremental impact of ₹74 crores toward employee benefits, fully provided for in the current financial year and disclosed as an exceptional item.
Nilima Prasad Divi: "I mean with the change in scenarios, I would say it's difficult to project, but we would say it would remain stable. And we would -- like it's also with the situation we are currently in, we wouldn't want to throw a figure on that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Double-digit growth; "that's the projection the company would like to assume it would achieve" | FY27 |
| Margin stability | Margins expected to "remain stable" vs current levels; no figure given | FY27 |
| Capex run-rate | Capex expected to be constant vs current year, unless a major new CS project or new project arises | FY27 |
| Dedicated CS commercialization | Three projects through validation, supplied to customers; commercialization depends on customer regulatory approvals | Hopeful by 2027, earlier or later |
| Freight cost pressure | Expected to continue in the near term; incorporated into planning | Coming quarters |
| Inventory build | Increase likely to be seen from Q1 as company secures and stores material | Q1 FY27 onward |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated total income | ₹2,986 cr |
| Profit before tax | ₹963 cr, vs ₹864 cr in Q4 FY25 |
| Profit after tax | ₹751 cr |
| Forex gain | ₹90 cr |
| Full-year consolidated total income | ₹11,067 cr, vs ₹9,712 cr in FY25 |
| Full-year profit before tax | ₹3,388 cr, after ₹74 cr Labour Codes impact; vs ₹2,916 cr in FY25 |
| Full-year profit after tax | ₹2,568 cr, vs ₹2,191 cr in FY25 |
| Full-year forex gain | ₹211 cr, vs ₹48 cr in FY25 |
| Full-year material consumption | 38.8% of sales revenue, vs 39.8% in FY25 |
| Full-year constant currency growth | 6.82% |
| Full-year product mix (Generics : CS) | 45% : 55% |
| Full-year nutraceuticals revenue | ₹946 cr, vs ₹781 cr in FY25 |
| Full-year export contribution | 89% of total sales revenue; Europe and US 74% of export revenue |
| Full-year assets capitalized | ₹1,544 cr, of which ~₹800 cr in Q4 |
| Capital work in progress (Mar 31, 2026) | ₹2,113 cr |
| Cash and cash equivalents (Mar 31, 2026) | ₹3,414 cr |
| Receivables (Mar 31, 2026) | ₹2,984 cr |
| Inventories (Mar 31, 2026) | ₹3,954 cr |
| Full-year capex | ~₹2,500 cr, ~23-24% of sales; vs ₹1,400 cr in FY25 |
| Full-year operating margin (excl. other income) | ~32-32.5% (per an analyst's math) |
| Labour Codes one-time impact (FY26) | ₹74 cr, fully provided as exceptional item |